iRadimed's Total Assets for the quarter that ended in Mar. 2026 was €98.95 Mil.
Warning Sign:
If a company builds assets at 27.1% a year, faster than its revenue growth rate of 20.5% over the past 5 years, it means that the company may be getting less efficient.
During the past 12 months, iRadimed's average Total Assets Growth Rate was 12.90% per year.
During the past 3 years, the average Total Assets Growth Rate was 27.90% per year.
During the past 5 years, the average Total Assets Growth Rate was 27.10% per year.
During the past 10 years, the average Total Assets Growth Rate was 20.20% per year.
During the past 13 years, iRadimed's highest 3-Year average Total Assets Growth Rate was 39.10%. The lowest was 10.40%. And the median was 27.90%.
Total Assets is connected with ROA %. iRadimed's annualizedROA % for the quarter that ended in Mar. 2026 was 20.99%. Total Assets is also linked to Revenue through Asset Turnover. iRadimed's Asset Turnover for the quarter that ended in Mar. 2026 was 0.20.
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
iRadimed's Asset Turnover for the quarter that ended in Mar. 2026 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
iRadimed Total Assets Related Terms
iRadimed Total Assets Historical Data
* Premium members only.
The historical data trend for iRadimed's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
iRadimed's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
iRadimed (FRA:46K) has a Total Assets of €98.95 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on iRadimed and its competitors.
Is iRadimed's Total Assets too high?
iRadimed's current Total Assets is €98.95 Mil. Overall, iRadimed has a GF Score™ of 87/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does iRadimed's Total Assets compare to AVNS and LMRI?
iRadimed's Total Assets of €98.95 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Medical Devices & Instruments company?
A good Total Assets depends on the Medical Devices & Instruments industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on iRadimed and its competitors. iRadimed's current Total Assets is €98.95 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is iRadimed stock overvalued right now?
Based on GuruFocus' analysis, iRadimed (FRA:46K) is currently considered Significantly Overvalued. The stock's GF Value™ is €56.24, compared to a current price of €84.50 — trading 50.2% above its estimated fair value. The current Total Assets is €98.95 Mil. iRadimed's overall GF Score™ is 87/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For iRadimed (FRA:46K), the current Total Assets is €98.95 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is iRadimed (FRA:46K) Overvalued in 2026?
Based on GuruFocus' analysis, iRadimed stock appears to be overvalued.
The current stock price of €84.50 is trading 50.2% above its estimated GF Value™ of €56.24.
GuruFocus considers iRadimed to be Significantly Overvalued.
Key valuation signals for FRA:46K:
Total Assets: €98.95 Mil
GF Value™: €56.24 vs. price of €84.50 (50.2% above fair value)
No single metric tells the full story. See the FRA:46K stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
iRadimed Corp develops, manufactures, markets, and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system, which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates the majority revenue from United States.
87GF Score
Get the complete analysis for FRA:46K
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:46K has been successfully added to your 
